STRAGEN   Report issue

For profit Phase 1 Phase 2
Founded: Geneva France (1990)
Status: No NME R&D (1990)

Organization Overview

First Clinical Trial
2013
NCT01808885
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Alaxia SAS | Stragen France

Active Ingredients

Drugs in Phase 2 Trials (2)

morphine (1 trial)

str-324 (2 trials)

Drugs in Phase 1 Trials (5)

alx-009 (1 trial)

bovine lactoferrin (1 trial)

cyanosulfoxylate (1 trial)

ifb-088 (1 trial)

Olesoxime (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 2)

Bronchiectasis (Phase 1)

Cystic Fibrosis (Phase 1)

Fibrosis (Phase 1)

Multiple Sclerosis (Phase 1)

Multiple Sclerosis, Relapsing-Remitting (Phase 1)

Sclerosis (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 7